Cambridge, UK and Indianapolis, US – 9 July 2019: Acacia Pharma Group plc ( the "Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that on 9 July 2019, the Directors and PDMR detailed in the notifications below purchased Ordinary Shares pursuant to the deferral of a proportion of their annual cash bonus earned in 2018. Both the Directors and the PDMR have undertaken to retain such shares until at least 31 December 2020.
The number of Ordinary Shares purchased by each Director and the PDMR is set out below:
Director Number of Ordinary Shares purchased
Julian Gilbert 6,043
Christine Soden 5,600
PDMR
Gabriel Fox 5,098
Following these trades, the beneficial interest of each Director and the PDMR in Ordinary Shares in the Company is as follows:
Director Number of Ordinary Shares held Percentage of issued share capital
Julian Gilbert 846,998 1.588%
Christine Soden 56,175 0.11%
PDMR
Gabriel Fox *328,576 0.62%
* Dr Fox holds 52,631 of these shares through Comedica Consulting Limited, a company owned by Dr Fox’s spouse.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details: